A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 19, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Chronic Hepatitis B Infection

Interventions

BIOLOGICAL

SN2001

100 µg, for subcutaneous (SC) injection

BIOLOGICAL

SN2001

200 µg, for subcutaneous (SC) injection

BIOLOGICAL

SN2001

300 µg, for subcutaneous (SC) injection

Trial Locations (1)

RECRUITING

Q-Pharm Pty Ltd., Herston

All Listed Sponsors

lead

Chimivac INC

INDUSTRY